Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals

Suganto Sutjipto, Niels C Pedersen, Chris J Miller, Murray B. Gardner, Carl V. Hanson, Agegnehu Gettie, Myra Jennings, Joanne Higgins, Preston A. Marx

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Eight rhesus macaques were immunized four times over a period of 8 months with a psoralen-UV-light-inactivated whole simian immunodeficiency virus vaccine adjuvanted with threonyl muramyl dipeptide. Eight unvaccinated control animals received adjuvant alone. Only the vaccinated animals made antibodies before challenge exposure to the viral core and envelope as determined by Western blotting (immunoblotting) and virus-neutralizing antibodies. Ten days after the final immunization, one-half of the vaccinated and nonvaccinated monkeys were challenge exposed intravenously (i. v.) and one-half were challenge exposed via the genital mucosa with virulent simian immunodeficiency virus. All of the nonvaccinated control monkeys became persistently infected. In spite of preexisting neutralizing antibodies and an anamnestic antibody response, all of the immunized monkeys also became persistently infected. However, there was evidence that the clinical course in immunized i.v. infected animals was delayed. All four mock-vaccinated i.v. challenge-exposed animals died with disease from 3 to 9 months postchallenge. In contrast, only one of four vaccinated i.v. challenge-exposed monkeys had died by 11 months postchallenge.

Original languageEnglish (US)
Pages (from-to)2290-2297
Number of pages8
JournalJournal of Virology
Volume64
Issue number5
StatePublished - 1990

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Macaca mulatta
genitalia
Haplorhini
monkeys
Vaccines
vaccines
Infection
Neutralizing Antibodies
neutralizing antibodies
infection
animals
Western Blotting
Acetylmuramyl-Alanyl-Isoglutamine
psoralen
Ficusin
antibodies
dipeptides
Ultraviolet Rays

ASJC Scopus subject areas

  • Immunology

Cite this

Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. / Sutjipto, Suganto; Pedersen, Niels C; Miller, Chris J; Gardner, Murray B.; Hanson, Carl V.; Gettie, Agegnehu; Jennings, Myra; Higgins, Joanne; Marx, Preston A.

In: Journal of Virology, Vol. 64, No. 5, 1990, p. 2290-2297.

Research output: Contribution to journalArticle

Sutjipto, Suganto ; Pedersen, Niels C ; Miller, Chris J ; Gardner, Murray B. ; Hanson, Carl V. ; Gettie, Agegnehu ; Jennings, Myra ; Higgins, Joanne ; Marx, Preston A. / Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. In: Journal of Virology. 1990 ; Vol. 64, No. 5. pp. 2290-2297.
@article{b5f2b5dcf7834993afbf7a936e5676b6,
title = "Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals",
abstract = "Eight rhesus macaques were immunized four times over a period of 8 months with a psoralen-UV-light-inactivated whole simian immunodeficiency virus vaccine adjuvanted with threonyl muramyl dipeptide. Eight unvaccinated control animals received adjuvant alone. Only the vaccinated animals made antibodies before challenge exposure to the viral core and envelope as determined by Western blotting (immunoblotting) and virus-neutralizing antibodies. Ten days after the final immunization, one-half of the vaccinated and nonvaccinated monkeys were challenge exposed intravenously (i. v.) and one-half were challenge exposed via the genital mucosa with virulent simian immunodeficiency virus. All of the nonvaccinated control monkeys became persistently infected. In spite of preexisting neutralizing antibodies and an anamnestic antibody response, all of the immunized monkeys also became persistently infected. However, there was evidence that the clinical course in immunized i.v. infected animals was delayed. All four mock-vaccinated i.v. challenge-exposed animals died with disease from 3 to 9 months postchallenge. In contrast, only one of four vaccinated i.v. challenge-exposed monkeys had died by 11 months postchallenge.",
author = "Suganto Sutjipto and Pedersen, {Niels C} and Miller, {Chris J} and Gardner, {Murray B.} and Hanson, {Carl V.} and Agegnehu Gettie and Myra Jennings and Joanne Higgins and Marx, {Preston A.}",
year = "1990",
language = "English (US)",
volume = "64",
pages = "2290--2297",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals

AU - Sutjipto, Suganto

AU - Pedersen, Niels C

AU - Miller, Chris J

AU - Gardner, Murray B.

AU - Hanson, Carl V.

AU - Gettie, Agegnehu

AU - Jennings, Myra

AU - Higgins, Joanne

AU - Marx, Preston A.

PY - 1990

Y1 - 1990

N2 - Eight rhesus macaques were immunized four times over a period of 8 months with a psoralen-UV-light-inactivated whole simian immunodeficiency virus vaccine adjuvanted with threonyl muramyl dipeptide. Eight unvaccinated control animals received adjuvant alone. Only the vaccinated animals made antibodies before challenge exposure to the viral core and envelope as determined by Western blotting (immunoblotting) and virus-neutralizing antibodies. Ten days after the final immunization, one-half of the vaccinated and nonvaccinated monkeys were challenge exposed intravenously (i. v.) and one-half were challenge exposed via the genital mucosa with virulent simian immunodeficiency virus. All of the nonvaccinated control monkeys became persistently infected. In spite of preexisting neutralizing antibodies and an anamnestic antibody response, all of the immunized monkeys also became persistently infected. However, there was evidence that the clinical course in immunized i.v. infected animals was delayed. All four mock-vaccinated i.v. challenge-exposed animals died with disease from 3 to 9 months postchallenge. In contrast, only one of four vaccinated i.v. challenge-exposed monkeys had died by 11 months postchallenge.

AB - Eight rhesus macaques were immunized four times over a period of 8 months with a psoralen-UV-light-inactivated whole simian immunodeficiency virus vaccine adjuvanted with threonyl muramyl dipeptide. Eight unvaccinated control animals received adjuvant alone. Only the vaccinated animals made antibodies before challenge exposure to the viral core and envelope as determined by Western blotting (immunoblotting) and virus-neutralizing antibodies. Ten days after the final immunization, one-half of the vaccinated and nonvaccinated monkeys were challenge exposed intravenously (i. v.) and one-half were challenge exposed via the genital mucosa with virulent simian immunodeficiency virus. All of the nonvaccinated control monkeys became persistently infected. In spite of preexisting neutralizing antibodies and an anamnestic antibody response, all of the immunized monkeys also became persistently infected. However, there was evidence that the clinical course in immunized i.v. infected animals was delayed. All four mock-vaccinated i.v. challenge-exposed animals died with disease from 3 to 9 months postchallenge. In contrast, only one of four vaccinated i.v. challenge-exposed monkeys had died by 11 months postchallenge.

UR - http://www.scopus.com/inward/record.url?scp=0025271057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025271057&partnerID=8YFLogxK

M3 - Article

C2 - 2157886

AN - SCOPUS:0025271057

VL - 64

SP - 2290

EP - 2297

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 5

ER -